Session Abstract – PMWC 2022 Silicon Valley


The PMWC 2022 Microbial Profiling Showcase will provide a 15-minute time slot for selected companies in the Microbiome and Pathogen ID fields. The human microbiome is composed of a wide variety of microorganisms that are essential for maintaining human health and preventing disease. Research in this area is accelerating due to the rapid development in genome sequencing technologies. This showcase will present some of the leading companies in microbial profiling and pathogen identification.


Confirmed Presenting Companies:

 Speaker Profile

Ph.D., CEO, EzBiome

Biography
Dr. Nur A Hasan is a molecular microbiologist with experiences in microbial genomics, microbiome, bioinformatics and molecular ecology. Dr. Hasan is the Chief Executive Officer of EzBiome Inc., USA. He received his Bachelor and Master’s in microbiology, M.B.A in Marketing and Ph.D. in Microbiology and Genomics. In his multidisciplinary research experience, Dr. Hasan contributed on various independent research projects in the field of infectious communicable diseases and led numerous large-scale genomic, metagenomic and microbiome projects that resulted in multiple patents, 80+ peer-reviewed articles, and over 100 abstracts and conference proceedings on microbiome, biomarker discovery, molecular ecology, and infectious diseases. Dr. Hasan taught numerous webinars and workshops on microbiome and bioinformatics and frequently present his research in scientific conferences nationally and internationally. He is an editorial board member of several scientific journals and continue to serve as ad doc reviewer for 18+ scientific journals.


Microbial Profiling Showcase:
EzBiome

EzBiome is a microbiome company which applies precision microbiome discovery platform to shorten the time for discovery and development of microbiota-based therapeutics and companion diagnostics for microbiome-related diseases.

EzBioCloud – An Advanced Microbiome Platform for Discovery of Exciting New Biology and Transformative Therapeutics!
The microbiome plays a critical role in human health and disease and Bioinformatics is the key to uncover cross-disciplinary microbiome data for novel biomarker discovery, product development, disease dynamics, effects of drugs on the microbiome and vice-versa. The presentation will showcase EzBioCloud Precision Microbiome Discovery Platform and demonstrates how it helps shorten the time for discovery and development of therapeutics and companion diagnostics for microbiome-related diseases.

 Speaker Profile

Ph.D., Director of Data Science and Bioinformatics, Diversigen

Biography
Tonya Ward is an accomplished microbiome scientist with expertise in clinical and experimental research, bioinformatics, next generation sequencing and translating data into insights. She's passionate about accelerating microbiome science through reproducible research and enabling high-power studies by creating services that scale. Tonya holds a Bachelor of Science in Genetics from the University of Western Ontario and a Ph.D. in Biochemistry from the University of Ottawa.


Microbial Profiling Showcase:
Diversigen

Diversigen empowers microbiome discovery through sequencing, analysis, and consulting services. The combined bench strength of Diversigen is unparalleled in the industry, providing you with access to those who are pioneering advancements in the microbiome field.

Metatranscriptomics: Enabling Biomarker Discovery

 Speaker Profile

Ph.D., VP, Research & Development, R&D, DNA Genotek Inc

Biography
Dr. Iwasiow completed a post-doctoral fellowship at the National Research Council of Canada and he holds a Ph.D. degree in Cellular and Molecular Medicine from the University of Ottawa. Dr. Iwasiow he has held various positions across Research and Product Development at DNA Genotek where he and his team contribute significantly to the company's patent portfolio in numerous areas including nucleic acid stabilization methods and physical sample collection devices. Dr. Iwasiow advanced his career within the organization, resulting in the appointment to his current role of Vice President of Innovation and Technology. Under his leadership, the team contributed to successful 510(k) clearances of Oragene•Dx, the first non-invasive DNA collection device for at-home and direct to consumer use. Most recently his team’s efforts lead to a 510(k) clearance of OMNIgene•GUT Dx, the first of its kind device for self-collection and stabilization of fecal samples for microbiome profiling.


Microbial Profiling Showcase:
DNA Genotek Inc

DNA Genotek Inc., Novosanis and Diversigen are subsidiaries of OraSure Technologies, Inc. working to provide high-quality sample collection products and comprehensive services for sample processing, sequencing, and bioinformatic analysis. Our solutions enable microbiome discovery for academic, pharmaceutical, biotechnology, agricultural and environmental applications.

A New Benchmark for Gut Microbiome Collections
DNA Genotek introduces OMNIgene®•GUT Dx, the first FDA-cleared device for the collection of human fecal samples and assessment of the microbiome profile. Validated using WGS, it provides a stable and reproducible representation of the in-vivo fecal bacterial community composition.

 Speaker Profile

Head Of Data Engineering, Second Genome

Biography
Satish is an innovator in data platforms, pioneering the development of complex computational pipelines, as well as novel machine-learning models designed to address critical challenges in various human diseases. Prior to Second Genome, Satish was part of many unicorn startups that successfully exited or went IPO, where he led the development of the platforms, scaled up technical stacks using modern software architecture and up leveled many teams. Satish mentors other engineering leaders regularly and wants to contribute more to the software community.


Microbial Profiling Showcase:
Second Genome

We are a tech-enabled biotech company. We built a proprietary platform turning microbial genetics into precision therapeutics and have cracked microbiome code. We are advancing a pipeline of precision therapeutics and biomarkers. We are delivering on collaborations and ready to make a difference for patients.

sg-4sight: Therapeutic Peptide and Biomarker Platform
Bacteria evoke changes in cells by producing and emitting peptides that can alter pathways for inflammation, transport, proliferation and metabolism. To discover these peptides and their targets, we built SG4Sight to collect clinical microbiome-data, conduct multi-technology meta-analysis, find the biomarkers, peptide therapeutic candidates.

 Speaker Profile

J.D., Vice President- Business Development, Karius Inc.

Biography
Mr. Kortschak has over 25 years experience developing and commercializing clinical diagnostic products across multiple technologies. His recent focus is supporting biomarker identification and biopharma support at Karius utilizing the non-invasive, liquid biopsy technology to detect mcfDNA in plasma.


Microbial Profiling Showcase:
Karius, Inc.

Karius utilizes an innovative liquid biopsy assay to identify over 1600 pathogens in plasma.

Microbial Profiling in Precision Medicine
The Karius test is used to discover new microbial biomarkers and develop assays that can help select patients, predict response, enable early detection, and monitor disease progression and remission.